Neuroprotective effects of receptor imidazoline 2 and its endogenous ligand agmatine

Neuroscience Bulletin

Volumn 22, Issue 3, 2006, Pages 187-191

  Qiu, Wei Wen ^a   Zheng, Rong Yuan ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Agmatine; Imidazoline; Ligand; Neuroprotection; Receptor

Indexed keywords

2 (2 BENZOFURANYL)IMIDAZOLE; AGMATINE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTAZOLINE; CALCIUM; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; IMIDAZOLINE; IMIDAZOLINE I2 RECEPTOR; IMIDAZOLINE RECEPTOR; ISOENZYME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ASTROCYTE; BINDING AFFINITY; BINDING SITE; BRAIN MITOCHONDRION; CALCIUM CELL LEVEL; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HYPOXIA; INJURY; ISCHEMIA; KIDNEY; LIVER MITOCHONDRION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OUTER MEMBRANE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVIEW; SEQUENCE HOMOLOGY;

EID: 33847774495     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984, 230: 232-236.
2. Ernsberger PR, Westbrooks KL, Christen MO, et al. A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 1992, 20 (Suppl 4): S1-S10.
3. Tesson F, Prip-Buus C, Lemoine A, et al. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochordrial outer membrance. J Biol Chem 1991, 266: 155-160.
4. 2 imidazoline ligands in intact cells. Mol Pharmacol 1997, 51: 637-643.
5. Garcia-Sevilla JA, Sastre M, Escriba PV. Age-dependent increases of immunoreactive imidazoline receptors in the human brain: possible association of a 29/30 kDa protein with the I2-imidazoline receptor identified by [3H]idazoxan. Neurosci Lett 1995, 184: 133-136.
6. Tesson F, Limon-Boulez I, Urban P, et al. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem 1995, 270: 9856-9861.
7. Raddatz R, Parini A, Lanier SM. Localization of the imidazoline binding domain on monoamine oxidase B. Mol Pharmacol 1997, 52: 549-553.
8. Ruggiero DA, Regunathan S, Wang H, et al. Distribution of imidazoline receptor binding protein in the central nervous system. Ann N Y Acad Sci 1995, 763: 208-221.
9. Liedtke W, Edelmann W, Bieri PL, et al. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 1996, 17: 607-615.
10. Liedtke W, Edelmann W, Chiu FC, et al. Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. Am J Pathol 1998, 152: 251-259.
11. 2-imidazoline receptor ligand LSL 60101. Br J Pharmacol 2000, 130: 1767-1776.
12. Zheng JQ, Weng XC, Gai XD, et al. Mechanism underlying blockade of voltage-gated calcium channels by agmatine in cultured rat hippocampal neurons. Acta J Pharmacol Sin 2004, 25: 281-285.
13. Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, et al. Protection by imidazoline drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 1999, 127: 1317-1326.
14. 2+ channels by antazoline. Neuroreport 2002, 14: 1711-1714.
15. Milhaud D, Fagni L, Bockaert J, et al. Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures. Neuropharmacology 2000, 39: 2244-2254.
16. 2-receptor and alpha 2-adrenoceptor binding in the hippocampus following transient global forebrain ischaemia in the rat. Neuroscience 1998, 82: 805-817.
17. Li G, Regunathan S, Barrow CJ, et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994, 263: 966-969.
18. Regunathan S, Piletz JE. Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes. Ann N Y Acad Sci 2003, 1009: 20-29.
19. Galea E, Regunathan S, Eliopoulos V, et al. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996, 316: 247-249.
20. Demady DR, Jianmongkol S, Vuletich JL, et al. Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. Mol Pharmacol 2001, 59: 24-29.
21. Satriano J, Matsufuji S, Murakami Y, et al. Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels. J Biol Chem 1998, 273: 15313-15316.
22. Ishizuka S, Cunard R, Poucell-Hatton S, et al. Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis. J Am Soc Nephrol 2000, 11: 2256-2264.
23. Babal P, Ruchko M, Campbell CC, et al. Regulation of ornithine decarboxylase activity and polyamine transport by agmatine in rat pulmonary artery endothelial cells. J Pharmacol Exp Ther 2001, 296: 372-377.
24. Su RB, Li J, Qin BY. A biphasic opioid function modulator: agmatine. Acta Pharmacol Sin 2003, 24: 631-636.
25. Berkels R, Taubert D, Grundemann D, et al. Agmatine signaling: odds and threads. Cardiovasc Drug Rev 2004, 22: 7-16.
26. Reis DJ, Yang XC, Milner TA. Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells. Neurosci Lett 1998, 250: 185-188.
27. Zhu MY, Piletz JE, Halaris A, et al. Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells. Cell Mol Neurobiol 2003, 23: 865-872.
28. Weng XC, Gai XD, Zheng J, et al. Agmatine blocked voltage-gated calcium channel in cultured rat hippocampal neurons. Acta Pharmacol Sin 2003, 24: 746-750.
29. Feng Y, Piletz JE, Leblanc MH. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 2002, 52: 606-611.
30. Kim JH, Yenari MA, Giffard RG, et al. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp Neurol 2004, 189: 122-130.
31. Yu CG, Marcillo AE, Fairbanks CA, et al. Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. Neuroreport 2000, 11: 3203-3207.
32. Gilad GM, Gilad VH. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci Lett 2000, 296: 97-100.